CD274 and nasopharyngeal carcinoma: Whereas the overall response rate to anti-PD-1/PD-L1 monotherapy in previously treated patients with R/M-NPC is only 20–30%6,7,9,10, which is not sufficient to improve clinical outcome in most patients.